Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group phase II study.
作者： Wolfram E. Samlowski , Holly Gundacker , J. Philip Kuebler , Jeffrey K. Giguere , Glenn M. Mills
关键词:
摘要: A phase II trial of gemcitabine(Gemzar®), a nucleoside analogue with broadactivity in solid tumors, was performed inpatients recurrent or metastaticsquamous cell carcinoma the head andneck. total 26 eligible patients wereregistered to receive dose of1250 mg/m2 weekly for 3 weeks,followed by 1 week rest. Toxicity wasevaluable patients. Nausea andvomiting occured 11 and 6 patients,repectively. Grade 4 hematologictoxicities were infrequent. Two patientsdeveloped neutropenic infections. Onepatient developed fatal liver failure whichwas thought due progressive livermetastases infection 14 days after asingle gemcitabine. There noobjective treatment responses (95% CI0–13%), median survival monthsin this highly resistant diseasepopulation. Gemcitabine is not consideredactive enough as monotherapy furtherevaluation disease population.
springer.com
sci-hub.se 参考文章(13)
J Carmichael, K Possinger, P Phillip, M Beykirch, H Kerr, J Walling, A L Harris, Advanced breast cancer: a phase II trial with gemcitabine. Journal of Clinical Oncology. ,vol. 13, pp. 2731- 2736 ,(1995) , 10.1200/JCO.1995.13.11.2731
A A Forastiere, B Metch, D E Schuller, J F Ensley, L F Hutchins, P Triozzi, J A Kish, S McClure, E VonFeldt, S K Williamson, Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. Journal of Clinical Oncology. ,vol. 10, pp. 1245- 1251 ,(1992) , 10.1200/JCO.1992.10.8.1245
Peng Huang, William Plunkett, Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemotherapy and Pharmacology. ,vol. 36, pp. 181- 188 ,(1995) , 10.1007/BF00685844
Axel-R Hanauske, Donna Degen, Martha H Marshall, Susan G Hilsenbeck, Gerald B Grindey, Daniel D Von Hoff, Activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units. Anti-Cancer Drugs. ,vol. 3, pp. 143- 146 ,(1992) , 10.1097/00001813-199204000-00012
Julie A. Kish, Arthur Weaver, John Jacobs, Glenn Cummings, Muhyi Al-Sarraf, Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck Cancer. ,vol. 53, pp. 1819- 1824 ,(1984) , 10.1002/1097-0142(19840501)53:9<1819::AID-CNCR2820530903>3.0.CO;2-R
J.B. Sørensen, Gemcitabine in non-small cell lung cancer Lung Cancer. ,vol. 12, ,(1995) , 10.1016/0169-5002(95)00433-2
C Jacobs, G Lyman, E Velez-García, K S Sridhar, W Knight, H Hochster, L T Goodnough, J E Mortimer, L H Einhorn, L Schacter, A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. Journal of Clinical Oncology. ,vol. 10, pp. 257- 263 ,(1992) , 10.1200/JCO.1992.10.2.257
G C Todd, L W Hertel, G B Boder, G A Poore, J S Kroin, G B Grindey, S M Rinzel, Evaluation of the Antitumor Activity of Gemcitabine (2′,2′-Difluoro-2′-deoxycytidine) Cancer Research. ,vol. 50, pp. 4417- 4422 ,(1990)
B. Lund, O. P. Hansen, K. Theilade, M. Hansen, J. P. Neijt, Phase II Study of Gemcitabine (2′,2′-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer Patients Journal of the National Cancer Institute. ,vol. 86, pp. 1530- 1533 ,(1994) , 10.1093/JNCI/86.20.1530
D Schrijvers, J Johnson, U Jiminez, M Gore, P Kosmidis, H Szpirglas, K Robbins, J Oliveira, R Lewensohn, J Schüller, A Riviere, C Arvay, P Langecker, H Jacob, E Cvitkovic, E Vokes, Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group. Journal of Clinical Oncology. ,vol. 16, pp. 1054- 1059 ,(1998) , 10.1200/JCO.1998.16.3.1054